Beone Medicines Ltd. Class ASSE: 688235

Announcement on the Handling of Relevant Tax Matters

Jun 27, 2026 · Issued by Beone Medicines Ltd. Class A via Shanghai Stock Exchange

Watch Beone Medicines Ltd. Class A explain itBeOne Medicines Ltd. (ONC) Q2 2026 Earnings Call · Replay · Aug 5

Announcement on the Handling of Relevant Tax Matters

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Earlier from Beone Medicines Ltd. Class A

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% ScaleJun 2
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell LymphomaMay 13
Report for Q1 2026May 12
BeOne Medicines Announces First Quarter 2026 Financial Results and Business UpdatesMay 6

All Beone Medicines Ltd. Class A news releases